Doravirine: a review.
| Autor: | Colombier MA; Department of Infectious Diseases, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris.; University of Paris Diderot Paris 7, Paris, France., Molina JM; Department of Infectious Diseases, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris.; University of Paris Diderot Paris 7, Paris, France. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current opinion in HIV and AIDS [Curr Opin HIV AIDS] 2018 Jul; Vol. 13 (4), pp. 308-314. |
| DOI: | 10.1097/COH.0000000000000471 |
| Abstrakt: | Purpose of Review: The current review addresses the role of doravirine (DOR), a novel once-daily nonnucleoside reverse transcriptase inhibitor (NNRTI) in first-line therapy at a time in which multiple options are available, and issues of antiviral efficacy, safety, simplicity and cost are critical to make informed decisions. Recent Findings: DOR combination regimens have been tested in two large randomized double-blinded clinical trials in treatment-naïve patients, showing noninferiority to ritonavir-boosted darunavir-based and efavirenz (EFV)-based regimens. The main features of DOR are reviewed in this report including its antiviral activity, genetic barrier to resistance, safety, once-daily dosing and coformulation in a single tablet with tenofovir disoproxil fumarate and lamivudine. DOR pharmacokinetics and drug-drug interactions are also reviewed as DOR can be given without food restriction and has no interaction with proton pump inhibitors. DOR has shown a superior safety profile than EFV regarding neuropsychiatric and cutaneous adverse events. DOR is currently being investigated in treatment-experienced patients and in those with transmitted NNRTI drug resistance. Summary: DOR is a promising new NNRTI that could become the preferred drug in its class for treatment initiation. DOR has shown excellent antiviral activity in treatment-naïve patients, a better safety profile than EFV and a low potential for drug-drug interactions. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|